Nuvilex, Inc. (OTCQB:NVLX), an emerging international biotechnology provider of cell and gene therapy solutions including encapsulation of live cells and services through their associate SG Austria, released information today about the therapeutic potential of the patent for treatment of HIV and Ebola viruses, Bird flu, SARS, and other infectious diseases.